Abstract All over the world people are surviving into their seventh and later decades of life more frequently today than ever before in human history. Some remain in good health, while others show chronic degenerative conditions (CDCs), frailty, and relatively rapid mortality. Thereafter, multiple factors promoting health and well-being become ever more complex as we age. After attainment of reproductive maturation, many physiological decrements occurring in concert with age reflect both senescent and disease processes, not simply the passage of time. Senescence is a process that begins with DNA, molecules and cells and ultimately terminates in cellular death, loss of organ function, and somatic frailty. These changes are different from benign changes with age that do not alter function. Both differ from the pathological processes represented by disease. Either disease or senescence may be age-related, but neither is age-determined. Disease results from pathological alterations and it affects all age groups. Diseases need not be related to senescence, which includes alterations due to inherent aspects of organismal biology. Distinctions among senescence, aging, and disease blur for the late-life CDCs because, in addition to disease processes, many CDCs are phenotypic manifestations of senescing DNA, organelles, cells, and organs. During earlier epochs of human evolution, greater environmental exposures and fewer cultural buffers likely lead to greater frailty and mortality before senescence progressed greatly, as they still do for most animals. In modern-day settings, culturally patterned behaviors have allowed human frailty to become disconnected somewhat from mortality, unlike non-human species.
Introduction
The major demographic change affecting populations worldwide during the 21st century is unlike any previous demographic transition. This one is affecting most the 50% of people who survive past their 70th birthday in cosmopolitan settings, and the ever-increasing percent of such survivors in less privileged settings. That so many are surviving to their 8th decade represents the first half of the present demographic transition. The second part is that thereafter, these septuagenarians are surviving longer as mortality rates continue to decline at older ages (Carey and Papadopoulos, 2005; Crews, 2005a; Doblhammer and Kytir, 2001) . Currently, in most cosmopolitan settings, mortality rates are declining faster at ages over 70 than at younger ages. Among those aged 65ϩ years, population growth rates during the next decade are projected to be the largest ever recorded as the "baby boom" generation becomes order. Population pyramids for many cosmopolitan nations already more resemble modern-day skyscrapers (Fig. 1b) than they do ancient Egyptian tombs (Fig. 1a ). Some populations with high fertility, high infant and childhood mortality, and low survival to age 65 still exist, such as India in 2000 (Fig. 2a) . Others, such as Japan in 2000 PE, already are top heavy and showing an elderly and a middle-age bulge from the post-war generation and their offering (Fig. 2b) . However, most nation states have transitioned to low fertility, low infant/child mortality, and high adult survival through the 6th and 7th decades. Those that have not yet done so or have regressed are found mainly in equatorial areas, regions of limited mineral, agricultural and industrial potential, and among those experiencing political, economic, and religious conflicts. A pattern of population growth among those aged 60ϩ and 80ϩ is consistent for the world population (Fig. 3) . Although rates of change differ substantially across and within populations, over the 20th and into the 21st centuries, mortality continued to shift rapidly to older and older ages (Crews 2005a) .
A Biocultural Perspective
A confluence of biological adaptations, environmental changes, and cultural developments over the past several thousand years have provided humankind with a bioculturallyconstructed niche (see Obling-Smee et al., 2003) . This built environment promotes retention of reserve capacity (RC) through reduced exposures to environmental (e.g., heat, cold, Senescence, Aging, and Disease
Douglas E. Crews
The Ohio State University, USA exposure) and infectious and parasitic agents (Crews, 2003 Crimmins and Finch, 2005; Drenos et al., 2006) . Alterations toward "cushy life styles" lived within built environmental niches have improved human health particularly during the earliest and latest phases of life history (LH). At older ages, health and illness are strongly determined by inherent biological stability (genetic and cellular propensities), life-long and ongoing biological modifications (wear-and-tear, senescence), environmental factors (stressors), history (age, period, cohort effects), and physiological function (allostatic load (AL), metabolic reserve capacity (RC), frailty) (Table 1) .
Resulting from these are complex physiological states we define as health, illness/disease, senescence, aging and wellness. Individually, each state is difficult to define and measure empirically. Jointly, they form a complex web of causality that we assess through change and disease. Assessing senescence requires understanding genetic, protein, cellular, tissue, organ, and organ system levels and interactions across levels. Even examining manifestations of senescence at the individual level to understand human variation over the lifespan requires applications of multiple assessments of disease, wellness, ADLs/IADLs, stress, perceptions of health, stress responses, and frailty, along with assessments of physiological and genetic risk factors. To properly intervene on disease and senescent processes, practioners and public health personnel need to differentiate between senescence, aging, and disease. A continuing question is whether differences between senescence, aging, and disease are conceptual or practical. The goal here is to examine differences between these states and to evaluate how well composite assessment scales, used to study human variation in physiological dysfunction during the last decades of life may measure the underlying senescent phenotype.
Senescence, Aging, and Disease
Senescence: Multiple definitions of senescence, aging, and disease litter the scientific literature (Arking, 2006; Crews, 2003; Cristofalo, 2000) . Occasionally, there is limited agreement over definitions even in a single edited volume (Esser and Martin, 1995) . Senescence mainly occurs during the LH phase from full maturity to death; it is characterized by an accumulation of metabolic byproducts and a decreased probability of reproduction and survival (Arking, 2006; Austad, 1992; Crews, 2003 Cristofalo, 2000; Finch and Rose, 1995; Kirkwood, 1981; Williams, 1957) . Contrary to many historical definitions, senescence is now viewed as age-independent. In addition, senescent processes are individualized, progressive, multifactorial, and deleterious (Arking, 2006) . Finally, senescence is an event-driven process affecting all organs and bodily systems, ultimately resulting from loss of reproductive potential, and leads to an increased probability of death (Arking, 2006; Austad, 1999; Crews, 2003) . Although senescence is not time-dependent, senescent changes accumulate over an organism's life span making it age-related (Arking, 2006; Crews, 2003) . This is partly because early life history (LH) events pace the timing of senescence (Crews, 2003) . And partly because, loss of function is dependent upon cellular processes of replication and differentiation that occur over biological time (Arking, 2006) . Senescence is not a programmed process. Senescence follows a different pace across species and between individuals within species. Variable patterns and timing of senescence are its hallmarks (Crews, 2003) . Senescent changes and longevity are poorly conserved phylogenetically. Rapid-and slow-senescing populations of wild mice, fruit flies, and mammals sharing the same family suggest that high variability in LH parameters is compatible with RS and population survival (Austad, 1997; Carey and Judge, 2001; Kirkwood and Austad, 2000; Rose et al., 2004) . In general, senescence commences with cessation of growth and development and attainment of maximum reproductive potential (MRP); (see Crews 2003 for a complete definition). Growth and development represent a co adaptive and allmetricly related series of events that begin at conception and proceed through completion of the adult soma (Arking, 2006; Crews, 2003) . Still, precursors of senescence may be observed as early as uterine development, infancy, and childhood (Barker, 1998; Cameron and Demerath, 2002) . As organisms survive beyond their point of MRP, NS becomes weaker because the probability of mortality from extrinsic and intrinsic factors becomes greater with increasing survival time (Kirkwood, 1981; Medawar, 1952; Rose, 1995; Weismann, 1889; Williams, 1957) . The force of natural selection (NS) declines with increasing time of survival after growth and development in most, but not all, sexually reproducing organisms. Senescent processes are cumulative, progressive, intrinsic, and deleterious (Arking, 2006) .
Aging: In contrast to senescence, aging measures the passage of time (Crews, 2003; 2005b) . As existence through time, aging may be counted as years, days, or minutes. Aging is neither a process nor is it a LH phase. All things, whether living or non-living age, only the living senescence. Elsewhere, we have described this with the homily that rocks and socks weather and wear with age, wine mellows with age, and humans take on different social and biological roles with age (Crews, 2003; Harper and Crews, 2000) . Many social, behavioral, cultural, life style, and biological changes affect people as they grow old in social settings. But, if these do not alter risks of death, then they are aging not senescence or (Crews, 2003) . Changes that increase the probability of death are senescence. All things age, but not all senesce. However, in common usage, aging represents the visible alterations in phenotype that individuals experience as they survive beyond their reproductive phase of LH (see Arking, 2006) Disease: Disease is different in kind from both senescence and aging. Processes with specific causes and characteristic symptoms that alter bodily functions, taking the soma away from homeostasis, are illnesses and disease. These may include non-apoptosis cell death, overgrowth of cells, pathogens, lack of essential nutrients, and inabilities to digest, metabolize, or excrete necessary and unnecessary substances. Diseases represent pathological processes and may resemble or act synergistically with senescent changes to affect the body. Disease often is not easily discernible from senescence nor is senescence easy to discern from disease. Specifically, some chronic degenerative conditions (CDCs) may themselves represent the observable manifestations of senescent changes at the cellular level (Arking, 2006 : Crews, 2003 Crews and Gerber, 1994; Cristofalo et al., 1999; Gerber and Crews, 1999; Johnson et al., 1995; Humpel and Grubeck-Loebenstein, 2005) .
Included among the manifestations of senescence are losses of DNA repair capabilities, impaired immune responses, and increased levels of stress markers in serum (Crews, 2003) . Mutant mtDNA and the proportion of mitochondria with altered mtDNA increase with age, reducing OXPHOS and cellular energy output. Myocytes die off from senescent alteration, decreasing cardiac output, while the ability to clear creatinine and nitrogen from the circulation decline. These progressive changes increase somatic fragility and frailty reducing survival and reproductive success. Aging does not intrinsically increase the probability of death. Aging includes graying and the loss of hair, deaths of relatives and friends, changing age-specific social roles, grandparenthood and greatgrandparenthood, and retirement from the labor force. Senescent changes are inherent to cells. They alter basic molecular and physiological processes. Diseases are somatic alterations that produce obvious symptoms. Often these may be treatable or alleviated by modern medical technology. Some CDCs likely are secondary to senescent alterations in cells. These include progressive bone loss and osteoporosis, progressive loss of immune function, increased markers of inflammation, neurological and skeletal alterations, and dementias such as Parkinson and Alzheimer's diseases. Each may progress to a variety of conditions including hip fracture, diabetes, septicemia, mobility loss, wasting, and metabolic dementias.
Many of the major risk factors for CDCs, such as obesity, hypertension, high serum cholesterol/lipids, hyperglycemia that predispose to life shortening CDCs may occur secondary to the breakdown of physiological defensive processes, loss of cells, and/or loss of organ reserves. Senescent processes contribute to many known risk factors for CDCs. Such findings suggest that CDCs may be visible signs of senescence (Crews, 2003; Cristofalo et al., 1999; Johnson et al., 1995) . In many ways, CDCs are secondary to cellular senescence processes that increase the probability of death (Crews, 2003; Cristofalo et al., 1999; Johnson et al., 1995) . Such interactions indicate that senescent-related changes at the cellular level produce changes at the whole soma level (Crews, 2003) . Methods to measure senescence of individuals reflecting changes at the cellular level are needed. Several methods have been proposed, and some have received broad support for partly accomplishing this goal. Activities of Daily Living/ Instrumental Activities of Daily Living (ADLs/IADLs) allostatic load, and frailty are the most widely used in current research and practice.
Human Variation Over the Life Span
Both prospective and retrospective data show that multiple physiological changes over the human life span are related to senescent alterations. Multiple attempts to identify "normal aging" and "biological age" have been made (Borkan and Norris, 1980) . Unfortunately, for the first, little seems to be normal with regard to human variability at older ages, although variation for multiple physiological traits seems to be reduced at increasing ages over about age 65 years (Crews, 2003) . Variation in many traits (e.g. blood pressure, height, serum cholesterol) increases with increasing age in the general population after attainment of MRP through about the 6th decade of life. However, coefficients of variation for most physiological and morphological traits tend to decrease with increasing age there after, particularly after the 8th decade of life. Biological age (BA) estimates were based upon concepts of deviations from average or normal values in population samples (Borkan et al., 1982) . Given their dependence on age, estimates of BA are little different for predicting longevity and disease than is age itself (Borkan and Norris, 1980) . For any aggregate measure to be a better predictor of senescent change than age, it should not be standardized on age. Indeed good biomarkers and composite estimates of senescence should be relatively poorly correlated with chronological age (Crews, 2003 (Crews, , 2005a . Genetological research does not need another proxy for chronological age. What are needed are biomarkers and scales that assess aspects of senescence that are not time dependant (Arking, 2006) . A scale to assess senescence should not be correlated with chronological age nor should it be based on age. Cellular and physiological biomakers should change independent of age, and scales should change with time in both positive and negative directions.
After, the limitations of BA and normal aging studies were revealed, the search for biomarkers of senescence began. Not age-determined, biomarkers were seen as aspects of cellular and physiological function whose alteration, appearance, or disappearance coincided with specific aspects of senescent biology (Arking, 2006) . Biomarkers are thought to scale with senescent change. An obvious biomarker of senescence in women is menopause. This alteration in ovarian function is associated with multiple phenotypic changes that conform to senescent change models. Lowering of serum estrogen at menopause increases rates of bone loss, ends reproductive capability, and enhances a number of disease processes (Austad, 1997; Peccei, 2001; Snowdon, 1990) . Biomarkers have been identified for a number of diseases and conditions (Arking, 2006) . If the concept is extended to genes, then specific predisposing alleles, such as those for Huntington's disease or coronary artery disease are clear biomarkers of senescence. Most biomarkers are not so clear cut. A number of biomarkers of senesence have been identified (Arking, 2006) . These range from hearing loss to slowed nerve conduction velocity. Many have been known for decades, while new ones are constantly being identified, c-reactive protein (CRP) and the interlukins (IL). Hopefully, continued study of biomarkers will lead to the development of interventions for senescent processes.
Assessing Somatic Declines
Stress responses: Allostatic load (AL) is a method of assessing physiological stress generated by both mentally and physically perceived stressors (Crews, 2007 in press; McEwen, 1997; Stewart, 2006) . AL is a composite assessment that cuts across multiple physiological domains that show responses to events occurring in the world outside one's soma. Stress inducing factors may be environmental (cold, heat, hypoxia). They also may include mental stress from anxiety, work performance, or public speaking. Variability in morbidity, mortality, and physical and cognitive function are highly correlated with estimates of AL (McEwen, 1998 (McEwen, , 2000 (McEwen, , 2003 McEwen and Seeman, 1999) . That AL may assess senescent somatic alterations is implicit in its design and applications (Crews, 2003 (Crews, , 2005b (Crews, , 2007 Stewart, 2006; McEwen, 1998 McEwen, , 2000 McEwen, , 2003 McEwen and Seeman, 1999) . Assessments of AL rely on various combinations of physiological measures scored as 1 in the highest quartile of risk and 0 in all others (McEwen, 2003; Stewart, 2006) . As originally constructed (McEwen, 1997 (McEwen, , 1998 , AL included 10 factors (Table 2) . Since then, dozens of physiological, metabolic, hormonal and biological measures have been examined as components of AL (reviewed by Stewart, 2006) . One suggestion is that AL may reflect variability in senescent decline among individuals within samples (McEwen and Seeman, 1999; Crews, 2007) . Although useful within populations, AL is difficult to interpret in cross-cultural comparisons (Crews, 2007 in press) .
Population-specific distributions of component risk factors reveal the broad range of human physiological variation compatible with reproductive success and long life. Combining samples from different populations into a hyper-population sample places all members of some populations at extremely low (Yanomami, Japanese) or high AL (American Samoans, African Americans). Among populations such as the Yanomami, Hazda, or Mieka few individuals may survive sufficiently long or have changes in risk factors sufficiently large to show senescence-related changes based upon such factors. While, in other populations such as Samoans or African Americans some individuals may show large changes very early in life. When multiple population samples are combined, their joint distribution shows how these latter groups all are at higher AL compared to more traditionalliving populations (Crews 2003 (Crews , 2007 .
Frailty: In nursing homes and community settings abilities to complete activities of daily living (Katz et al., 1963) are frequently used to assess disability and the need for assistance in living or nursing home placement (Crews and Zavotka, 2006) . ADLs also are used as a proxy for frailty and senescence when more appropriate measurements are not available. This has lead to an intensified search for ways to assess frailty in living humans. Frailty is a complex biological phenomenon that is closely associated with pathology and disease (Fried et al., 2004; Hogan et al., 2003; Morley et al., 2002; Walston, 2005) , making it difficult to quantify physiologically. Frailty may be a better measure of senescent alterations in humans than in other animals. Given humankind's abilities to care for members of their families and groups, frailty in humans has to a large extent been disconnected from mortality, but not morbidity and dependence (Crews, 2005b) . Loss of ability to complete ADLs provides a measure of dependence on others, thereby indirectly assessing the ability of human social systems to alter the strong association of frailty with mortality observed in other species .
As with AL, a number of composite assessment scales of frailty have been developed and tested. One problem is that frailty scales should not assess disease pathology. For example, the Clinical Global Impression of Change in Physical Frailty (CGIC-PF) is a consensus-based scale. It was developed by a team of clinicians, patients, caregivers, and other "experts" (Studenski et al., 2004) . CGIC-PF includes assessments of mobility, endurance, balance, nutrition, strength, and neuromotor performance, along with 7 medical complexity variables -health care use, appearance, ADLs, self-perceived health, and emotional and health status (Studenski et al., 2004) . This is a complex scale, and may not be useful for field assessments. The CGIC-PF scale is expected to change as an individual's innate disability alters over time and this is incorporated as a sliding scale from 1-7, with 1 indicating marked worsening of health and 7 marked improvements in health (Studenski et al., 2004) . Therefore change may be used to gauge an individual's personal trajectory of disability over time. Walston (2004 Walston ( , 2005 and colleagues (Fried et al., 2001; Walston et al., 2002 ) developed a frailty-screening exam based on muscle weakness, slow walking speed, fatigue, weight loss, and low activity levels that may be used in field research. This simple index shows positive associations with future hospitalization and death (Walston, 2005) . It also is associated with multiple metabolic markers indicative of poor function in older adults. Several specific metabolic markers, increases in IL-6, C-reactive protein and white blood cells, are associated with senescent changes in cells. These also are indicators of inflammation (Walston, 2005) . Elsewhere inflammation has been labeled the fire of senescence (Fried et al., 2001) . One model of frailty is that it starts with sarcopenia and reduced expenditure of energy; this leads to weight loss, weakness, exhaustion, and low levels of physical ability, i.e. frailty (Fried et al., 2001; Walston, 2005) . Frailty predicts falls, and is associated with declining mobility, loss of ADLs, and death (Fried et al., 2001; Walston, 2005) . Both DHEA-S and CRP are included in frailty composites, suggesting that the nueroendocrine and inflammatory/immune systems are intimately involved in senescent alterations at the cellular level.
Discussion
Unraveling senescence, aging, and disease will be a difficult process. However it may be necessary in order to progress in our understanding of senescence. This starts with developing ways to measure and assess the senescent phenotype. Multiple avenues of research are leading to a decomposition of senescence, aging, and disease. Senescence arises as the probability of reproduction decreases. This leads to a declining force of natural selection with increasing time of survival. Unfortunately, natural selection can not prevent the increasing probability of mortality that occurs secondary to senescence. To untangle disease from senescence we must acknowledge that many age-related CDCs reflect cellular senescence. There is synergism between the 2 domains, emphasizing the need to develop age and disease-independent assessments of senescent change at the cellular level that may be used to disentangle senescence and disease in the whole organism. Measures of AL, ADLs/IADLs, and frailty need to be correlated with assessments of DNA expression and protein profiles, because the latter are the markers of cellular senescence. To fully integrate these processes it will be necessary to add DNA profiles, and high-risk and longevity-enhancing alleles to studies of disease and senescence. Then we may start to untangle the threads of senescene and disease processes.
